Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Association of IDH1 mutations with survival and recurrence in resected intrahepatic cholangiocarcinoma received or not received adjuvant chemotherapy.

The oncologist - 10 Apr 2026

Wang Pengcheng, Li Ning, Ye Yuhang, Pu Jing, Sun Rongqi, Luo Chubin, Hu Zhiqiang, Zhou Zhengjun, Li Jia, Zou Jixue, Fan Jia, Zhou Jian, Zhou Shaolai

Abstract excerpt

BACKGROUND: IDH1 mutations are causal in tumor development and progression; however, their association with disease characteristics, prognosis, and therapy response in patients with resected intrahepatic cholangiocarcinoma (ICC) remains controversial. MATERIALS AND METHODS: In this cohort study, we recruited 803 patients who underwent curative resection for ICC at a single hospital in China. We performed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Bile Duct Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chemotherapy, Adjuvant

Share to Cholangiocarcinoma

Share to Disease-Free Survival

Share to Isocitrate Dehydrogenase

Share to Neoplasm Recurrence, Local

Share to Prognosis

Source

Open in PubMed Open full text

Identifiers

PMID: 41955332
DOI: 10.1093/oncolo/oyag124
PMCID: PMC13092374

Genes

IDH1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association of IDH1 mutations with survival and recurrence in resected intrahepatic cholangiocarcinoma received or not received adjuvant chemotherapy.PMID 41955332Read ↗

Mutation Rate of IDH1 and the Impact of Pathological Features on Survival in Intrahepatic CholangiocarcinomaSemantic proximity Read ↗

Impact of IDH1 mutation on clinical course of patients with intrahepatic cholangiocarcinoma: a retrospective analysis from a German tertiary center.Semantic proximity Read ↗

Evaluating the Prognostic Impact of IDH Mutations in Intrahepatic Cholangiocarcinoma.Semantic proximity Read ↗

Clinical Outcomes After Progression on First-Line Therapies in IDH1 Mutated Versus Wild-Type Intrahepatic Cholangiocarcinoma Patients.Semantic proximity Read ↗

Differential isocitrate dehydrogenase 1 and isocitrate dehydrogenase 2 mutation-related landscape in intrahepatic cholangiocarcinoma.Semantic proximity Read ↗

Next-generation sequencing analysis of cholangiocarcinoma identifies distinct IDH1-mutated clusters.Semantic proximity Read ↗

Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets.Semantic proximity Read ↗

Molecular profile and its clinical impact of IDH1 mutated versus IDH1 wild type intrahepatic cholangiocarcinoma.Semantic proximity Read ↗

Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma.Semantic proximity Read ↗

Distinct clinical and prognostic implication of IDH1/2 mutation and other most frequent mutations in large duct and small duct subtypes of intrahepatic cholangiocarcinoma.Semantic proximity Read ↗

Isocitrate Dehydrogenase-Mutated Cholangiocarcinoma: Natural History and Clinical Outcomes.Semantic proximity Read ↗

Characteristics of genomic alterations in Chinese cholangiocarcinoma patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.